TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05640947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Hot AXIOS™ Stent and Electrocautery-Enhanced Delivery System
Description: EUS-guided gastro-gastrostomy using the Hot Axios device: Using a therapeutic endoscopic ultrasound endoscope with a working channel of 3.7mm and under fluoroscopic control, the excluded stomach will be identified and punctured with a 19G needle. Contrast injection will confirm the good position of the needle in the excluded stomach. If needed, the excluded stomach will be filled with blue-stained aqua (5% indigocarmine) until a sufficient distension is obtained for placement of the lumen-apposing metal stent. A lumen-apposing metal stent with a diameter of 20mm will be used according to the manufacterers' instructions to create a gastrogastrostomy. Position will be checked with fluoroscopy.
Study: NCT06575751

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Broad Spectrum Cannabidiol (bsCBD) 400 mg
Description: Participants in this Arm will take 400 mg of bsCBD daily. Participants will take medication by mouth with food in the morning and evening.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Broad Spectrum Cannabidiol (bsCBD) 200 mg
Description: Participants in this Arm will take 200 mg of bsCBD daily. Participants will take medication by mouth with food in the morning and evening.
Study: NCT05046457

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-cryptoxanthin (BCX)
Description: Subjects will be randomised into one of the three study treatment arms.
Study: NCT06575751

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in this Arm will take a medically inert placebo. Participants will take medication by mouth with food in the morning and evening.
Study: NCT05430529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Smoke Cessation Service
Description: Both of the intervention group and control group will receive standard smoke cessation service, which is same as usual practice.
Study: NCT06262633

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Targeted Microwave Ablation (TMA) for localized prostate cancer using organ based tracking (OBT) navigation
Description: Targeted microwave ablation (TMA) is a novel treatment developed for focal treatment of prostate cancer, and it is applied with precise navigation guidance under the organ-based tracking (OBT) mechanism.
Study: NCT05273606

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiSight mutifocal soft contact lens
Description: Subjects will wear MiSight™ multifocal soft contact lenses for 1 month.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proclear 1 Day soft contact lens
Description: Proclear™ 1 Day soft contact lens will be worn for baseline evaluation.
Study: NCT05430529

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Smoke Cessation Service
Description: Both of the intervention group and control group will receive standard smoke cessation service, which is same as usual practice.
Study: NCT05906498

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetyl cysteine
Description: N-acetyl cysteine (NAC) is synthetic cysteine amino acid, which in turn elevate the glutathione level in the body, which have important direct antioxidant activity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetyl cysteine
Description: N-acetyl cysteine (NAC) is synthetic cysteine amino acid, which in turn elevate the glutathione level in the body, which have important direct antioxidant activity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: vitamin E possessing an anti-inflammatory action
Study: NCT04901130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer-aided Real-time Automatic Quality Control System (AQCS)
Description: Automatic quality-control system(AQCS), developed based on deep convolutional neural network (DCNN) models, could improve the colonoscopists' performance during withdrawal phase and significantly increase polyp and adenoma detection.
Study: NCT05691699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-903
Description: Capsule; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-903
Description: Capsule; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-903
Description: Capsule; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-903
Description: Capsule; oral
Study: NCT05430529

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Short Advice for Control Group
Description: If the control group participant encountering difficulties in smoke cessation caused by alcohol usage, HCP will provide short advice to them. Participant will be urged not to drink during smoke quitting. If drinking is unavoidable, participant should not drink exceed the low-risk drinking portion recommended by Department of Health, which is 2 standard alcohol units for men and 1 stand alcohol unit for women per day. HCPs will remind participants to aware their drinking portion, in order to quit smoke successfully.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Alcohol Intervention for Intervention Group
Description: During the face-to-face smoking cessation counseling session, HCPs will first play a 2 - 3 minutes short video with electronic devices to participants who are allocated to the intervention group.~After the short video, HCPs will ask participants to share their thoughts and willingness of alcohol control. Participants are expected to show 4 responses: (1) refuse to attempt alcohol control; agree to attempt alcohol control that (2) quit drinking totally, (3) quit drinking for 2 weeks, or (4) reduce the alcohol consumption. HCPs will deliver personalized advice according to participants' choices and encourage them to receive the WhatsApp message reminders.~In all participants, HCPs will invite them to receive WhatsApp messages reminders for incoming 4 weeks (3 messages per week).~In addition, HCPs can choose to discuss with participants the reasons for consuming alcohol.~Nevertheless, HCPs can also choose to provide AUDIT-based brief intervention to the participants.
Study: NCT05691699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-903
Description: Capsule; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-903
Description: Capsule; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Capsule; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Capsule; oral
Study: NCT05663931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DM Discharge Toolkit
Description: The DM Discharge Toolkit is a multi-modal intervention consisting of a 3-D printed DM survival kit that stores DM self-care supplies (e.g., glucose meter) and technical skills (e.g., injection) simulation materials (e.g. simulation skin), whose use is integrated with a website (https://mydiabeteskit.com) containing standardized DM Survival education content.
Study: NCT05117931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Patients will receive amivantamab weekly for the first cycle, and biweekly subsequently at a dose of 1050mg (\<80kg) or 1400mg (\>80kg). The first day of dosing is considered Cycle 1 Day 1. Each cycle is 28 days in duration. The initial dose will be administered over 2 days to prevent infusion reactions. For patients who weigh \<80 kg, amivantamab 350mg IV will be given on Cycle 1 Day 1, and the remaining 700mg IV will be given on Cycle 1 Day 2. Patients will continue to receive amivantamab 1050mg IV once a week during Cycle 1 then biweekly (Days 1 and 15) of each subsequent Cycle. For patients who weigh ≥ 80 kg, 350mg IV amivantamab will be given on Cycle 1 Day 1 and 1050mg IV will be given on Cycle 1 Day 2. Patients will continue to receive amivantamab 1400mg IV once a week during Cycle 1 then biweekly (Days 1 and 15) of each subsequent Cycle.
Study: NCT04839315

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: mRNA COVD19 vaccine
Description: Subjects will receive two doses of mRNA based COVID19 vaccines.
Study: NCT05258435

Intervention type: DEVICE
Intervention: NuVasive Simplify Cervical Artificial Disc
Description: Simplify Disc is a weight-bearing cervical artificial disc implant consisting of PEEK (polyetheretherketone) endplates and one semi-constrained, fully articulating, mobile Zirconia Toughened Alumina ceramic (ZTA) core.
Study: NCT06256731

Intervention type: DEVICE
Intervention: Eye-Tracking
Description: Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
Study: NCT05262933

Intervention type: OTHER
Intervention: coffee
Description: It will be given to patients brewed coffee to drink and evaluated to hypotension and post spinal puncture headache

Intervention type: OTHER
Intervention: Water
Description: It will be given to patients water to drink and evaluated to hypotension and post spinal puncture headache
Study: NCT04878250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Description: 4 doses of bintrafusp alfa (1200mg flat dose) administered intravenously at 14 day intervals before undergoing radical cystectomy.
Study: NCT05700929

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication skills training for nurses
Description: Aim of the developed training will be to foster patient-centered communication skills of nursing professionals in Germany. The training consists of four modules in which participating nurses will get information regarding patient-centeredness and general communication techniques. Participants will also learn how to response to patients in escalating situations and how to communicate with seriously ill or dying patients. The underlying framework for the training is the Calgary-Cambridge Guide, a well-known model for structuring conversation with patients. Different didactic techniques (i.e. roll-play, video sequences, group discussion) will be applied. The training will be provided in small groups of 10-14 participants each. Two facilitators will give the training, one of them being a nursing professional trained according to the train-the-trainer approach, the other being a member of the research group, who was involved in the development of the training.
Study: NCT05883020

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Experimental Interventions
Description: One session per week of rSWT will be applied using the BMI-1120 SHOCK MED device (BIO-MED-INC- ITALY). The following parameters will be used: Shocks number: 1500 per muscle, will be applied over the belly of the calf muscle using the 15 mm applicator head. The pressure will be 2 bar and the frequency will be 4 Hz. Patients will receive shock wave from prone position.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard physical therapy program
Description: Regular rehabilitation procedures consist of strengthing, stretching, facilitation and inhibitory techniques, splinting, developmental techniques, gait and balance training, and advice to parents. The duration of each session will be 1 hour, 3 times per week for 4 weeks
Study: NCT05899478

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tyknot® Suture-Mediated Closure System
Description: Arterial closure to ensure hemostasis at femoral artery puncture points

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Perclose® ProGlide Suture-Mediated Closure System
Description: Arterial closure to ensure hemostasis at femoral artery puncture points
Study: NCT06566066

Intervention type: OTHER
Intervention: no intervention
Description: register study without intervention

Intervention type: OTHER
Intervention: no intervention
Description: register study without intervention
Study: NCT01368679

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoprothesis Implantation
Description: stent implantation in the abdominal artery using endovascular
Study: NCT04908956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib is a Tyrosine Kinase Inhibitor (TKI). It is an irreversible inhibitor of Epidermal Growth Factor Receptors (EGFRs) harboring sensitising-mutations (EGFRm) and TKI-resistance mutation T790M.~The appropriate number of osimertinib tablets (80 mg or 40 mg if the dose is reduced due to toxicity) will be provided to patients to be self-administered at home.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: SBRT will be delivered using risk-adapted SBRT with a maximum of 5 SBRT fractions.
Study: NCT05251415

Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: Blood will be taken in larger quantity.
Study: NCT05027009

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Examination
Description: Undergo total body exam

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Examination
Description: Undergo total body exam

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Examination
Description: Undergo total body exam

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Solar Simulated Light
Description: Undergo exposures to simulated sunlight

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Solar Simulated Light
Description: Undergo exposures to simulated sunlight

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Solar Simulated Light
Description: Undergo exposures to simulated sunlight
Study: NCT06534788

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reciprocal Inhibition MET
Description: Reciprocal Inhibition MET will be applied to the shortened piriformis muscle in supine and prone positions with participants using 30-50% of their maximum voluntary isometric contraction. It will include 30-50% isometric contraction of the muscle opposite to the muscle to be stretched for 7-10 seconds, followed by inhalation, exhalation and rest period of 5 seconds and then a stretch (through the new barrier with patients' assistance) of 10-60 seconds hold. RI-MET group will receive 3-5 repetitions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-facilitation MET
Description: Post-facilitation stretch technique for shortened piriformis muscle in supine and prone positions will be applied with participants using 20% of their maximum voluntary isometric contraction. It will include 20% maximal isometric contraction of the muscle to be stretched for 6-10 seconds, followed by a rapid stretch (through the new barrier) of 15 seconds hold. After stretch, the muscle is allowed to relax in the midrange for up to 30 seconds. PFS-MET group will receive 3-5 repetitions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: TENS and hot pack application to provide heating effect over the painful area (10 minutes) Both groups will receive conventional physical therapy which they will be taught as a home plan. Following exercises are guided to the patient as home plan.~* Resisted abduction with Thera/resistance band~* Resisted bridging with Thera/resistance band~* Resisted clam exercise with Thera/resistance band

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: TENS and hot pack application to provide heating effect over the painful area (10 minutes) Both groups will receive conventional physical therapy which they will be taught as a home plan. Following exercises are guided to the patient as home plan.~* Resisted abduction with Thera/resistance band~* Resisted bridging with Thera/resistance band~* Resisted clam exercise with Thera/resistance band
Study: NCT05437627

Intervention type: DIAGNOSTIC_TEST
Intervention: The Arabic version of Stuttering Severity Instrument-3 (ASSI3) for children and adults
Description: Assessment of stuttering severity: The Arabic version of Stuttering Severity Instrument-3 (ASSI3) for children and adults will be applied for assessment of severity of stuttering. (3).~Automatic detection and severity assessment of stuttering using MATLAB version 8.1.0.604 R2013a (7). Stuttering detection system has three main steps which are acoustic processing, feature extraction and classification/recognition
Study: NCT06205524

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TI-0010
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TI-0010
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TI-0010
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TI-0010
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study: NCT05669391

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Genomic analysis of antidepressants
Description: Genomic analysis of all antidepressants. Tris EDTA anticoagulation and salting out were used to extract DNA. OD 260/280 was between 1.6-1.8 and the concentration was greater than 50 ng/ μ L。 Using the PCR gene chip detection method and the Asian Screening Array (ASA) chip detection technology of Illumina Company (this chip is the first whole genome SNP chip designed based on the whole genome sequencing data of 9000+East Asian populations, which contains 750000 markers, with 85% of the effective loci), we can obtain the genetic information of polymorphic loci related to the individual differences of drug effects of subjects.
Study: NCT05784727

Intervention type: DEVICE
Group type: OTHER
Intervention: Earswitch device
Description: The Earswitch™ device consists of an earpiece made from silicon or similar bio-compatible material and incorporates a miniature camera. The earpiece sits within the ear canal and is not in direct contact with the eardrum and the camera is not in contact with the ear-canal. The camera detects voluntary movement from the tensor tympani muscle as presented at the eardrum and the Earswitch system translates this movement to an external virtual keypad or similar to allow the patient to communicate nonverbally.
Study: NCT06040489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine 50mg
Description: Oral Miltefosine 50mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine 50mg
Description: Oral Miltefosine 50mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400mg
Description: Oral Pentoxifylline 400mg tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400mg
Description: Oral Pentoxifylline 400mg tid
Study: NCT05761132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: neoadjuvant immunotherapy
Study: NCT04979065

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics, Vitamin D
Description: Combination of two supplement that given separately
Study: NCT06040489

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Amphotericin B
Description: Intravenous 25 to 40mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Amphotericin B
Description: Intravenous 25 to 40mg/kg
Study: NCT04587440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic inclination measurement
Description: Ultra-sound based measurements of the pelvic inclination lying, standing and seating position. EOX X-ray in seating position.
Study: NCT04979065

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with inactive ingredient
Study: NCT05224479

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional workflow triage
Description: Workflow triage is based on order location, STAT designation, and first-in-first-out status.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Traditional workflow triage
Description: Workflow triage is based on order location, STAT designation, and first-in-first-out status.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional workflow triage
Description: Workflow triage is based on order location, STAT designation, and first-in-first-out status.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Machine learning workflow triage
Description: Workflow triage is based on the machine learning model's confidence of abnormality.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Machine learning workflow triage
Description: Workflow triage is based on the machine learning model's confidence of abnormality.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Machine learning workflow triage
Description: Workflow triage is based on the machine learning model's confidence of abnormality.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Random workflow triage
Description: Workflow triage is based on random order.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Random workflow triage
Description: Workflow triage is based on random order.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Random workflow triage
Description: Workflow triage is based on random order.
Study: NCT04694131

Intervention type: DEVICE
Group type: OTHER
Intervention: TMS
Description: The intervention of interest will be TMS delivered to the region of the left posterior parietal cortex with the greatest connectivity with the left hippocampus derived from the baseline resting-state fMRI session. This region was chosen because of its dense connections with the hippocampus, allowing stimulation of this location to modulate function of the hippocampal-cortical network. The control intervention target will be vertex, a commonly used active control site which does not influence neural or behavioral activity.
Study: NCT05114265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUR-101
Description: Single oral dose of KUR-101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUR-101
Description: Single oral dose of KUR-101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OxyNorm
Description: Single oral dose of OxyNorm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral dose of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral dose of placebo
Study: NCT05676879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice massage was applied to the SP6 points
Description: Ice massage was applied to the SP6 points (SP6 point is located 3-4 fingers above the posterior malleolus bone, that is, 4 fingers above the ankle) of the pregnant women in first stage of childbirth at 4-5 cm, 6-7 cm, and 8-9 cm cervical dilatations during 3 contractions.